NNVC Nanoviricides (NNVC) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001379006
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
17
13F, latest reported quarter
Nanoviricides insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for NANOVIRICIDES, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
no insider purchases or sales on record
0 transactions on record
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
17 funds bought in last quarter
below 71% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
3.7% of the float short (float per yahoo 2026-10-26) · 1.1 days to cover · settled 2026-09-30
below 56% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch NNVC
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-4.9%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns NNVC: institutional holders (13F)
13F holdings, latest reported quarter
919,313 sh
$1.3M
216,022 sh
$298.2K
185,217 sh
$255.6K
158,753 sh
$219.1K
131,923 sh
$182.1K
Congress trades in NNVC
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
NNVC planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
NNVC mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$49.7K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$217.9K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$338.6K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$81.4K position · as of 2026-05-31
0.0%
VANGUARD BALANCED INDEX FUND
$28.3K position · as of 2026-06-30
0.0%
VANGUARD TOTAL STOCK MARKET INDEX FUND
$901.8K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 17 funds added last quarter. Each figure is a federal filing, dated the day it went public.
NNVC financials
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM NNVC
| FY Jun 2026 | $0 |
| FY Jun 2025 | $0 |
| FY Jun 2024 | $0 |
| FY Jun 2023 | $0 |
| FY Jun 2022 | n/a |
| Jun 2026 | $0 |
| Mar 2026 | $0 |
| Dec 2025 | $0 |
| Sep 2025 | $0 |
| Jun 2025 | $0 |
| Mar 2025 | $0 |
| Dec 2024 | $0 |
| Sep 2024 | $0 |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Net margin, TTM NNVC
| FY Jun 2026 | n/a |
| FY Jun 2025 | n/a |
| FY Jun 2024 | n/a |
| FY Jun 2023 | n/a |
| FY Jun 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$7.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM NNVC
| FY Jun 2026 | -$7.8M |
| FY Jun 2025 | -$8.5M |
| FY Jun 2024 | -$6.5M |
| FY Jun 2023 | -$5.8M |
| FY Jun 2022 | -$6.2M |
| Jun 2026 | -$2.1M |
| Mar 2026 | -$1.9M |
| Dec 2025 | -$2.0M |
| Sep 2025 | -$1.7M |
| Jun 2025 | -$1.7M |
| Mar 2025 | -$2.0M |
| Dec 2024 | -$2.2M |
| Sep 2024 | -$2.6M |
At each fiscal year end
Single quarter
Debt to equity
0.54x
long-term 2018-03-31 (100 months older than the period end) plus current 2017-03-31 (112 months older than the period end); equity 2026-06-30
Debt to equity NNVC
| FY Jun 2026 | 0.54x |
| FY Jun 2025 | 0.63x |
| FY Jun 2024 | 0.41x |
| FY Jun 2023 | 0.32x |
| FY Jun 2022 | 0.20x |
| Jun 2026 | 0.54x |
| Mar 2026 | 0.52x |
| Dec 2025 | 0.43x |
| Sep 2025 | 0.66x |
| Jun 2025 | 0.63x |
| Mar 2025 | 0.54x |
| Dec 2024 | 0.46x |
| Sep 2024 | 0.47x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-1.63x
TTM operating cash flow over long-term 2018-03-31 (100 months older than the period end) plus current 2017-03-31 (112 months older than the period end)
Cash flow to debt NNVC
| FY Jun 2026 | -1.63x |
| FY Jun 2025 | -1.79x |
| FY Jun 2024 | -1.34x |
| FY Jun 2023 | -1.20x |
| FY Jun 2022 | -1.25x |
| Jun 2026 | -1.63x |
| Mar 2026 | -1.54x |
| Dec 2025 | -1.55x |
| Sep 2025 | -1.58x |
| Jun 2025 | -1.79x |
| Mar 2025 | -1.75x |
| Dec 2024 | -1.74x |
| Sep 2024 | -1.64x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-101.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity NNVC
| FY Jun 2026 | -101.5% |
| FY Jun 2025 | -99.7% |
| FY Jun 2024 | -63.0% |
| FY Jun 2023 | -45.3% |
| FY Jun 2022 | -30.6% |
| Jun 2026 | -101.5% |
| Mar 2026 | -90.0% |
| Dec 2025 | -77.5% |
| Sep 2025 | -94.0% |
| Jun 2025 | -99.7% |
| Mar 2025 | -99.8% |
| Dec 2024 | -82.0% |
| Sep 2024 | -81.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-87.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets NNVC
| FY Jun 2026 | -87.9% |
| FY Jun 2025 | -87.5% |
| FY Jun 2024 | -55.8% |
| FY Jun 2023 | -42.5% |
| FY Jun 2022 | -30.2% |
| Jun 2026 | -87.9% |
| Mar 2026 | -79.9% |
| Dec 2025 | -69.8% |
| Sep 2025 | -80.9% |
| Jun 2025 | -87.5% |
| Mar 2025 | -90.5% |
| Dec 2024 | -75.0% |
| Sep 2024 | -69.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital NNVC
| FY Jun 2026 | n/a |
| FY Jun 2025 | n/a |
| FY Jun 2024 | n/a |
| FY Jun 2023 | n/a |
| FY Jun 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-102.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed NNVC
| FY Jun 2026 | -102.5% |
| FY Jun 2025 | -101.1% |
| FY Jun 2024 | -61.2% |
| FY Jun 2023 | -45.3% |
| FY Jun 2022 | -30.6% |
| Jun 2026 | -102.5% |
| Mar 2026 | -90.9% |
| Dec 2025 | -78.2% |
| Sep 2025 | -95.1% |
| Jun 2025 | -101.1% |
| Mar 2025 | -101.3% |
| Dec 2024 | -83.4% |
| Sep 2024 | -78.6% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing NNVC
| FY Jun 2026 | n/a |
| FY Jun 2025 | n/a |
| FY Jun 2024 | n/a |
| FY Jun 2023 | n/a |
| FY Jun 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$36.6M
market value at close 2026-10-26 on 2026-09-28 shares, plus long-term 2018-03-31 (100 months older than the period end) plus current 2017-03-31 (112 months older than the period end), minus cash 2026-06-30
Enterprise value NNVC
| FY Jun 2026 | $31.8M |
| FY Jun 2025 | $25.7M |
| FY Jun 2024 | $20.3M |
| FY Jun 2023 | $10.0M |
| FY Jun 2022 | $12.4M |
| Jun 2026 | $31.8M |
| Mar 2026 | $21.2M |
| Dec 2025 | $19.9M |
| Sep 2025 | $28.5M |
| Jun 2025 | $25.7M |
| Mar 2025 | $20.5M |
| Dec 2024 | $21.3M |
| Sep 2024 | $22.9M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-22.4%
TTM free cash flow over market value at close 2026-10-26
FCF yield NNVC
| FY Jun 2026 | -26.0% |
| FY Jun 2025 | -37.9% |
| FY Jun 2024 | -31.9% |
| FY Jun 2023 | -43.4% |
| FY Jun 2022 | -28.6% |
| Jun 2026 | -26.0% |
| Mar 2026 | -37.5% |
| Dec 2025 | -36.5% |
| Sep 2025 | -30.4% |
| Jun 2025 | -37.9% |
| Mar 2025 | -45.9% |
| Dec 2024 | -40.9% |
| Sep 2024 | -36.0% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing NNVC
| FY Jun 2026 | n/a |
| FY Jun 2025 | n/a |
| FY Jun 2024 | n/a |
| FY Jun 2023 | n/a |
| FY Jun 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2026-06 | 2025-06 | 2024-06 | 2023-06 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating income | -$8.3M | -$9.6M | -$8.5M | -$8.9M |
| Net income | -$8.2M | -$9.5M | -$8.3M | -$8.6M |
| EPS (diluted) | -0.41 | -0.63 | -0.70 | -0.74 |
| Operating cash flow | -$7.7M | -$8.5M | -$6.3M | -$5.7M |
| Cash | $2.8M | $1.6M | $4.8M | $8.1M |
SEC XBRL, fiscal years, as known on 2026-10-28
NNVC Stock Sonar score 4/7 axes
Find similar shapesCompareNNVC ranks highest on risk and compliance (80th percentile) and financial health (38th), and lowest on profitability (28th), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
